What distinguishes a Section 361 tissue allograft from a Section 351 biologic drug?

Section 361 HCT/Ps are minimally manipulated tissues intended for homologous use that do not depend on living cell metabolic activity for their primary function, allowing them to be marketed without pre-market FDA approval. Section 351 products involve systemic effects, metabolic activity, or more-than-minimal manipulation, classifying them as biologic drugs requiring extensive pre-market approval and clinical trial data.

What documentation must a clinical practice retain for administered allografts?

Practices must maintain complete lot-level traceability linking the recipient patient record to the specific donor tissue unit. This includes keeping donor eligibility records, product tracking numbers, storage temperature records, and detailed clinical chart notes reflecting homologous use.

Can Section 361 allografts be marketed for systemic disease treatment?

No. Marketing or applying Section 361 allografts for systemic, neurological, or disease-modifying conditions violates the homologous use requirement. Tissue allografts under Section 361 must be used strictly for structural applications matching their original tissue function, such as repair, replacement, or cushioning.

How does minimal manipulation apply to liquid or membrane tissue allografts?

For structural tissues such as skin or amniotic membranes, processing cannot alter the structural integrity or mechanical properties of the original tissue matrix. Practices should audit vendor technical sheets to verify that tissue processing relies solely on standard cleaning, sizing, or preservation rather than chemical digestion or cell isolation.

FDA Section 361 Compliance for Human Tissue Allografts

FDA Section 361 compliance requirements for human tissue allografts demand that tissue products meet strict criteria for minimal manipulation and homologous use without relying on cellular metabolic activity. To maintain regulatory compliance under 21 CFR Part 1271, clinical practices must verify vendor cGTP facility registration, donor screening protocols, and chain-of-custody records for all /biologics. This guide outlines the essential operational checkpoints practice managers must enforce during vendor procurement to mitigate regulatory exposure.

Understanding 21 CFR 1271: Section 361 vs Section 351

The U.S. Food and Drug Administration (FDA) regulates Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) under Title 21 of the Code of Federal Regulations, Part 1271. Within this framework, HCT/Ps fall under one of two primary regulatory pathways: Section 361 or Section 351 of the Public Health Service (PHS) Act.

Section 361 HCT/Ps are regulated solely to prevent the introduction, transmission, and spread of communicable diseases. Products qualifying under Section 361 do not require pre-market approval, Biologics License Applications (BLA), or pre-clinical Investigational New Drug (IND) filings. This distinction allows clinical practices to procure and utilize structural tissue allografts efficiently within standard outpatient workflows.

Conversely, if an HCT/P fails to meet all Section 361 criteria, it is categorized as a Section 351 biologic product, drug, or medical device. Section 351 products require extensive clinical trials, FDA approval prior to marketing, and strict drug manufacturing oversight. For practice managers evaluating biologics, maintaining absolute clarity on these boundaries is vital to safeguarding practice operations and avoiding regulatory enforcement action.

The Four Core Pillars of Section 361 Compliance

For a human tissue allograft to maintain its Section 361 designation, it must meet all four conditions set forth under 21 CFR 1271.10(a). Failure to satisfy even a single condition reclassifies the product under Section 351.

1. Minimal Manipulation

Minimal manipulation processing requirements vary depending on whether the tissue performs a structural or non-structural function in the donor:

Structural Tissue: Processing must not alter the original relevant characteristics of the tissue relating to its utility for reconstruction, repair, or replacement. Structural tissues include bone, skin, tendons, ligaments, and amniotic membrane.
Non-Structural Tissue: Processing must not alter the relevant biological characteristics of the tissue. Examples include hematopoietic stem cells or reproductive cells.

Actions such as extensive enzymatic digestion, cellular isolation, or chemically breaking down extracellular matrix structures generally cross the threshold into structural alteration, taking the product outside Section 361.

2. Homologous Use Only

Homologous use means the tissue performs the same basic function or functions in the recipient as it performed in the donor. The tissue must be used for structural repair, coverage, cushioning, or support in location and context similar to its anatomical design.

Compliant Example: Utilizing an amniotic fluid or tissue graft to provide a protective barrier or structural covering over damaged connective tissue.
Non-Compliant Example: Marketing or applying tissue allografts with claims to treat systemic, metabolic, neurological, or cardiovascular conditions.

3. Non-Combination with Other Agents

The HCT/P must not be combined with another drug, device, or synthetic agent, except for water, crystalloids, or sterilizing, preserving, or storage agents that do not raise new safety concerns.

4. Systemic Effect and Metabolic Dependence

The product must not depend on the metabolic activity of living cells for its primary function, and must not have a systemic effect, unless it is intended for autologous use, allogeneic use in first- or second-degree blood relatives, or reproductive use.

Vendor Auditing Checklist for Practice Administrators

Operational administrators must establish a formal vendor verification protocol before introducing any human tissue allograft into their clinical catalog. Practice managers can review regulatory protocols and vendor documentation via our FAQ and compliance resources.

Use the following checklist when evaluating prospective tissue manufacturers and distributors:

[ ] FDA Registration & Listing: Verify that the tissue processor holds an active FDA Establishment Registration and has properly listed every HCT/P product code.
[ ] cGTP Compliance: Request documentation demonstrating adherence to Current Good Tissue Practice regulations (21 CFR Part 1271, Subpart D).
[ ] Donor Eligibility Screening Protocols: Confirm that donor selection criteria involve comprehensive testing for communicable diseases (including HIV, Hepatitis B/C, Syphilis, HTLV, and West Nile Virus) by CLIA-certified laboratories.
[ ] Processing Methodologies: Inspect vendor technical sheets to confirm processing relies solely on minimal manipulation without chemical alteration or enzymatic digestion.
[ ] Lot Traceability Controls: Ensure the vendor provides detailed Certificates of Analysis (CoA) and single-donor unit tracking tags with every shipment.
[ ] Storage and Shipping Logs: Verify that cold-chain shipping standards (e.g., ambient, refrigerated, or cryopreserved protocols) are monitored with temperature indicators.

Clinical Operational Integration: Clinical Insights

From a clinical workflow standpoint, integrating compliant Section 361 tissue products requires coordination between administrative oversight and clinical execution. For specialists in orthopedic practice and subspecialty fields, tissue allografts serve as valuable structural matrices.

Clinicians must ensure that clinical documentation explicitly reflects homologous intent. Chart notes should specify structural goals—such as defect coverage, tissue scaffolding, or mechanical cushioning—rather than non-homologous therapeutic claims. Clear documentation bridges administrative compliance with high-standard clinical care, establishing a defensible clinical record during third-party or regulatory reviews.

Risk Mitigation and Recordkeeping Workflows

Establishing compliant internal processes prevents supply chain bottlenecks and clinical liabilities. Administrators should implement the following three-tier recordkeeping standard:

Receipt and Quarantine: Upon delivery, inspect package integrity, cold-chain temperature strips, and Certificates of Compliance. Record lot numbers and tissue expiration dates in an inventory ledger prior to releasing the tissue for clinical use.
Patient Chart Mapping: Attach the specific tissue allograft identifier tag directly to the patient’s electronic health record (EHR). The record should note tissue lot number, expiration date, clinical site of application, treating provider, and precise anatomical application.
Adverse Event Protocols: Maintain a documented protocol for reporting unexpected tissue reactions or suspected communicable disease transmission to both the tissue supplier and the FDA MedWatch program as mandated by federal guidelines.

What This Means for Your Practice

Navigating FDA Section 361 compliance is an ongoing operational commitment, not a one-time audit. To protect your practice while offering structural tissue options:

Audit Existing Vendors: Re-evaluate all biological inventory against the four pillars of Section 361 compliance.
Update Informed Consent & EHR Templates: Ensure patient consent forms and clinical chart templates emphasize structural, homologous applications.
Standardize Receipt Protocols: Train staff to verify donor eligibility documentation and temperature indicators before adding shipments to active inventory.
Align Procurement with Licensed Distributors: Partner with verified suppliers who maintain strict compliance standards, clear chain-of-custody documentation, and regulatory transparency.

For guidance on selecting fully compliant structural tissue allografts and integrating regenerative technologies into your clinical workflow, connect with the team at Dallas Regenerative Solutions by visiting our contact page.